At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09606 DUALITYBIO-B
Market Closed 12-12 16:08:09
326.200
+13.200
+4.22%
High328.200Low303.400Vol618.11K
Open314.800D1 Closing313.000Amplitude7.92%
Mkt Cap28.99BTradable Cap28.99BTotal Shares88.88M
T/O197.08MT/O Rate0.70%Tradable Shares88.88M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Duality Biotherapeutics Inc. Proposes 2025 Share Scheme for Shareholder Approval at Upcoming EGM
Reuters  ·  18:06
Duality Biotherapeutics Inc. Proposes 2025 Share Scheme for Shareholder Approval at Upcoming EGM
HK Stock Connect Shareholding Changes | December 8
Stock News  ·  12-08
HK Stock Connect Shareholding Changes | December 8
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Tiger Newspress  ·  12-04
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Tiger Newspress  ·  12-03
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Are Investors Undervaluing Duality Biotherapeutics, Inc. (HKG:9606) By 49%?
Simply Wall St.  ·  12-02
Are Investors Undervaluing Duality Biotherapeutics, Inc. (HKG:9606) By 49%?
Southbound Capital Flow Data (T+2) for Dec 2
Stock News  ·  12-02
Southbound Capital Flow Data (T+2) for Dec 2
CISI FIN Initiates Coverage on DUALITYBIO-B (09606) with "Overweight" Rating, Highlights Leadership in Next-Gen ADC Innovation
Stock News  ·  11-28
CISI FIN Initiates Coverage on DUALITYBIO-B (09606) with "Overweight" Rating, Highlights Leadership in Next-Gen ADC Innovation
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
Tiger Newspress  ·  11-26
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Tiger Newspress  ·  11-24
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
HK Stock Connect Holdings Change Report | Nov 20
Stock News  ·  11-20
HK Stock Connect Holdings Change Report | Nov 20
Analysis of Hong Kong Stock Connect Holdings as of November 19
Stock News  ·  11-19
Analysis of Hong Kong Stock Connect Holdings as of November 19
HK Stock Movement | DUALITYBIO-B (09606) Rises Over 8% Again as DB-1418 Granted FDA Fast Track Designation and Approved for Clinical Trials in China
Stock News  ·  11-13
HK Stock Movement | DUALITYBIO-B (09606) Rises Over 8% Again as DB-1418 Granted FDA Fast Track Designation and Approved for Clinical Trials in China
HK Movers | Biomedical Stocks Jump With BeOne Medicines and Biocytogen up 7%
Tiger Newspress  ·  11-13
HK Movers | Biomedical Stocks Jump With BeOne Medicines and Biocytogen up 7%
HK Stock Connect Shareholding Changes | Nov 13
Stock News  ·  11-13
HK Stock Connect Shareholding Changes | Nov 13
HK Stock Movement | DUALITYBIO-B (09606) Rises Nearly 3% in Early Trading as DB-1418 Receives FDA Fast Track Designation
Stock News  ·  11-12
HK Stock Movement | DUALITYBIO-B (09606) Rises Nearly 3% in Early Trading as DB-1418 Receives FDA Fast Track Designation
HK Stock Connect Shareholding Changes | November 12
Stock News  ·  11-12
HK Stock Connect Shareholding Changes | November 12
HK Stock Connect Shareholding Changes | Nov 11
Stock News  ·  11-11
HK Stock Connect Shareholding Changes | Nov 11
HK Movers | Biomedical Stocks Jump With Ascletis Pharma up 9%
Tiger Newspress  ·  11-10
HK Movers | Biomedical Stocks Jump With Ascletis Pharma up 9%
Southbound Capital Flow Statistics (T+2) for Hong Kong Stocks | November 5
Stock News  ·  11-05
Southbound Capital Flow Statistics (T+2) for Hong Kong Stocks | November 5
HK Short Interest Data as of October 31
Stock News  ·  10-31
HK Short Interest Data as of October 31

Introduction

Company Name.
DUALITYBIO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.
Issue price:
--